Industry landscapes
The companies, capital and talent shaping age tech and longevity in the United Kingdom. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
No company example met every recorded classification, independence and public-profile gate in this snapshot. The live directory may have newer qualifying companies.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
6 of 271 tracked companies have open roles.
57 of 271 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 119 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 71.1% of disclosed capital, while 79.0% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $16.93M | 14 | 10 |
| 2017 | $89.29M | 19 | 12 |
| 2018 | $57.91M | 29 | 12 |
| 2019 | $26.25M | 15 | 11 |
| 2020 | $126.29M | 38 | 14 |
| 2021 | $82.98M | 10 | 17 |
| 2022 | $417.24M | 10 | 15 |
| 2023 | $72.4M | 8 | 4 |
| 2024 | $8.09M | 1 | 4 |
| 2025 | $201.14M | 1 | 7 |
Share of all disclosed company funding.
137 recorded rounds since 2016
Recorded participation in age tech and longevity company rounds since 2016.
Backed by Vanderbilt University and Kairos and others.
Backed by BDT & MSD Partners and Schroders Capital and others.
Participating investors were not recorded in this snapshot.
Backed by Kairos and Yabeo and others.
Backed by Bain Capital Life Sciences and Omega Funds and others.
Backed by Jeito and SV Health Investors and others.
Participating investors were not recorded in this snapshot.
Backed by Highland Europe and Keen Venture Partners and others.
Backed by Yabeo and Peter Sands and others.
Backed by Legal & General and Accelerated Digital Ventures.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · company accounts; aggregate reporting threshold not met · 4 reporting entities from 111 eligible matches.
Sum of reporting-entity revenue; not the United Kingdom market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
None of 4 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 4 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| Memory Tracks ↗10791734 | £0.1m | £0.0m | +10.9% | — | — |
| Project Vae ↗12423682 | £0.0m | £0.0m | +3.5% | — | — |
| Buddi ↗08119445 | £0.0m | £2.0m | +21080.7% | — | — |
| MyFinanceFuture ↗12419441 | £0.0m | £0.0m | +61.5% | — | — |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the the United Kingdom companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
38 of these companies (14%) publish at least one Android app — 53 apps in all, carrying 1.8M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| OurTime: Dating App for 50+Ourtime | 710.6K | 4.4 | Dating |
| Scottish WidowsScottish Widows | 537.8K | — | Finance |
| Nymbl TrainingNymbl Science | 115.2K | 4.6 | Health & Fitness |
| Penny PensionPenny | 89.7K | — | Finance |
| Pensions By PenfoldPenfold | 62.2K | — | Finance |
| Curam - For CarersCuramcare | 53.3K | — | Health & Fitness |
| CareLineLiveCare Line Live | 41K | — | Business |
| Cera CareCera | 23.2K | — | Health & Fitness |
| Curam - Find a carerCuramcare | 19.5K | — | Health & Fitness |
| Cur8 by IFGIslamic Finance Guru | 17.1K | — | Finance |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q2–2026Q1).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Investment Tech | 8 | 714.1K | Scottish Widows 537.8K | |
| Healthcare It | 14 | 187.9K | Nymbl Training 115.2K | |
| Local Services | 9 | 118.8K | Curam - For Carers 53.3K | |
| Healthcare Booking Platforms | 8 | 118.7K | Cera Care 23.2K | |
| Sme Business Management Software | 3 | 41.1K | CareLineLive 41K | |
| Assistive Tech | 23 | 27.1K | buddi Connect 8.5K | |
| Disease Self Management | 20 | 20.5K | Eagle Mobile 2.7K | |
| Wearable Technology | 17 | 19.4K | CanaryCare 2.2K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 38 of 53 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
5 companies hiring · $939.49M disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Chesnara plc (LON:CSN) has to announced that it has entered into an agreement to acquire 100% of the issued share capital of Scottish Widows Europe SA, a Luxembourg based closed life insurance business, from Scottish Widows Limited for total cash consideration of €110 million.
Over the last few weeks, Sinclair has continued to reinforce to Scripps its willingness to engage on a proposed Sinclair-Scripps combination.
Croatian-founded GlycanAge has raised $8.7 million (€7.4 million) in a targeted funding round to accelerate the clinical development of its technology and expand access to glycan testing for clinicians worldwide.
Three female co-founded HealthTech startups in Glasgow—Silver Lion Innovations, Seluna, and Smplicare—have raised over €1.1 million in early-stage funding to fast-track their innovative healthcare solutions to market.
Merck has acquired three companies in relatively small “bolt‑on” deals: EyeBio (for $1.3 billion upfront and potentially up to $3 billion overall), ...
CareLineLive has secured a majority investment from technology-focused investment firm Accel-KKR.
Workplace pensions platform Penfold lands £3.9m ($5.3m) to scale digital offering.
Cera said it is making an eight-figure investment into the facility
Lyfeguard has today announced that Mark Allcock has joined the company as Co-founder and Chief Technology Officer (CTO), strengthening its leadership team as the business enters its next stage of growth focused on building resilient, secure infrastructure for managing life’s essential information.
Top 10 categories among 105 recorded events in the 24-month window.
6 tracked people moves
Retirement Previously chief compliance officer
Appointment Co-founder and Chief Technology Officer
Appointment Vice President and General Manager
Appointment Chairman
Retirement Previously Vice President and General Manager
Products, platforms and features in the recorded window
AI Agent
Robot Technology Platform
AI compliance software
3 recorded events
construction haltedMachias City Officials
project halted due to building-permit violationsCity officials of Machias, Maine
approvedMachias City Officials
Reported company results in the recorded window.
Median across 13 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| chesnara→Scottish Widows ↗ | Announced | 2026-02-17 | Not stated in snapshot |
| Sinclair→The EW Scripps Company | Announced | 2026-01-19 | Not stated in snapshot |
| Sinclair→E.W. Scripps Co. | Announced | 2025-12-17 | Not stated in snapshot |
| Sinclair→E. W. Scripps Company | Announced | 2025-11-24 | Not stated in snapshot |
| Sinclair→the e.w. scripps company | Completed | 2025-11-17 | Not stated in snapshot |
| Sinclair→E.W. Scripps Class A shares | Announced | 2025-11-17 | $15.6M |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
0 postings in the preceding 12 months. The full 4-posting snapshot covers 2 employers.
0 tracked postings mention remote work.
3 postings specify a level.
| Company | Open roles |
|---|---|
| LYMA Life ↗ | 4 |
| EyeBio ↗ | 3 |
| Arquella ↗ | 1 |
| Connected Health ↗ | 1 |
| Willday Wealth Management ↗ | 1 |
| Equal Care ↗ | 1 |
| Company | Employees |
|---|---|
| Scottish Widows ↗ | 2,192 |
| Connected Health ↗ | 380 |
| Lifted ↗ | 90 |
| Cera ↗ | 60 |
| My Pension Expert ↗ | 57 |
| LYMA Life ↗ | 26 |
| Penfold ↗ | 22 |
| GlycanAge ↗ | 22 |
124 founders and chief executives across 91 companies.
BuildingMinds, Cera, ex-XOM Materials, McKinsey. Czech Technical University in Prague BASc 2009, Johannes Kepler University Linz MSc 2011
Venture Capitalist - SV Health Investors. Yale University Bachelor of Science 1982
Ex-CustomerFirst Renewables, A Better City, Solar Design Associates. University of Maine at Farmington BS 2010, Harvard University 2016…
MD Balance Research Foundation, Maimonides Medical Center, NYU Hospital for Joint Diseases. Columbia Presbyterian Medical Center 1995
Ex-Handy HQ, Co-Founder Mopp.com, DLA Piper. University of Sheffield LLB 2007, PhD 2008
University Of Massachusetts Lowell, ex-Harte Hanks, ex-Panasonic, Northeastern University, 1997
Hub71 · Ex - Co-Founder Lime Street, Foresight Institute, On Deck. University of the Arts London BA 2014
Ex- McKinsey & Company, Cabinet Office, University of Warwick BA 2010, University of Oxford MPhil 2012
CareLineLive.
ex- Vantage Partners, CFE, Meridian Productivity, Tyburn Lane East London. Trinity College BA 1989, University College Dublin DBS
Ex-Founder SquareStudio, Marks and Spencer. University of Sussex BA 2011
Co-Founder IslamicFinanceGuru, ex- Shaykh Akram Nadwi, Debevoise & Plimpton, Ashurst, 1st Ethical, Co-Founder Design Molvi…
22 profiles with education records.
4 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
51,685 papers in the recorded worldwide scope.
Tone counts: 44,341 positive · 4,434 neutral · 2,910 negative.
Landmark: The Emerging Evidence of the Parkinson Pandemic
Landmark: The essence of senescence: Figure 1.
Landmark: The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression
Common problems researchers identify · 0117.9% of this theme group
Examines lifespan limits, sustainability concerns, and evolutionary factors influencing longevity across species.
Longevity (789) · Sustainability (26) · Longevity risk (44) · Dentistry (19)
Immunity and longevity
An evolutionary perspective of lifespan and epigenetic inheritance
| Year | Share index |
|---|---|
| 2022 | 66.7 |
| 2023 | 68.6 |
| 2024 | 76.9 |
| 2025 | 56.4 |
Common problems researchers identify · 0217.7% of this theme group
Explores how oxidative damage, proteostasis loss, and immune decline drive age‑related diseases.
Disease (173) · Oxidative stress (88) · Senescence (217) · Immune system (91)
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Happily (n)ever after: Aging in the context of oxidative stress, proteostasis loss and cellular senescence
| Year | Share index |
|---|---|
| 2022 | 3963.5 |
| 2023 | 3922.0 |
| 2024 | 3713.8 |
| 2025 | 4034.7 |
Common problems researchers identify · 0316.8% of this theme group
Investigates senescent cell biology, its role in tissue degeneration, and links to cancer.
Senescence (779) · Cellular senescence (176) · Cell biology (198) · Cancer research (53)
Cellular Senescence in Intervertebral Disc Aging and Degeneration: Molecular Mechanisms and Potential Therapeutic Opportunities
Senescence under appraisal: hopes and challenges revisited
| Year | Share index |
|---|---|
| 2022 | 2760.4 |
| 2023 | 3504.4 |
| 2024 | 2581.2 |
| 2025 | 1581.5 |
Common problems researchers identify · 0415.8% of this theme group
Discusses demographic shifts, frailty, ageism, and the need for inclusive aging policies.
Gerontology (336) · Longevity (573) · Healthy aging (114) · Population ageing (98)
Longevity, Frailty and Ageism.
The Longevity Revolution: Challenges and Opportunities for an Inclusive Ageing Society
| Year | Share index |
|---|---|
| 2022 | 1858.2 |
| 2023 | 1831.5 |
| 2024 | 2184.7 |
| 2025 | 1406.9 |
Common problems researchers identify · 0514.8% of this theme group
Analyzes how reproductive strategies and ecological pressures affect lifespan evolution.
Reproduction (111) · Fecundity (77) · Longevity (368) · Ecology (64)
Evolution of ageing, costs of reproduction and the fecundity–longevity trade-off in eusocial insects
Distinct genomic signals of lifespan and life history evolution in response to postponed reproduction and larval diet in<i>Drosophila</i>
| Year | Share index |
|---|---|
| 2022 | 380.4 |
| 2023 | 351.8 |
| 2024 | 390.0 |
| 2025 | 348.7 |
Common problems researchers identify · 0611.9% of this theme group
Looks at life expectancy variations across populations, education levels, and gender.
Life expectancy (293) · Demography (179) · Longevity (426) · Population (119)
Longevity and Education: A Demographic Perspective
Gender and longevity
| Year | Share index |
|---|---|
| 2022 | 1289.8 |
| 2023 | 1253.8 |
| 2024 | 1053.8 |
| 2025 | 789.5 |
Common problems researchers identify · 075.0% of this theme group
Focuses on telomere maintenance, telomerase activity, and their impact on aging and disease.
Telomere (240) · Telomerase (91) · Senescence (117) · Genome instability (20)
Telomeres and aging: on and off the planet!
Telomere in Aging and Age-Related Diseases
| Year | Share index |
|---|---|
| 2022 | 59.2 |
| 2023 | 72.2 |
| 2024 | 65.3 |
| 2025 | 72.8 |
Cautions · 0119.7% of this theme group
Highlights how senescent changes in mesenchymal cells may limit therapeutic efficacy.
Senescence (413) · Cell biology (140) · Mesenchymal stem cell (73) · Cancer research (55)
Senescence induces fundamental changes in the secretome of mesenchymal stromal cells (MSCs): implications for the therapeutic use of MSCs an
NK Cell Senescence in Cancer: From Molecular Mechanisms to Therapeutic Opportunities
| Year | Share index |
|---|---|
| 2022 | 2802.3 |
| 2023 | 3536.7 |
| 2024 | 2615.8 |
| 2025 | 1653.7 |
Cautions · 0219.4% of this theme group
Examines how age‑specific reproduction influences senescence and individual fitness in wild populations.
Reproduction (104) · Population (104) · Longevity (208) · Reproductive success (52)
Age-specific reproduction in a long-lived species: the combined effects of senescence and individual quality
Individual variation in rates of senescence: natal origin effects and disposable soma in a wild bird population
| Year | Share index |
|---|---|
| 2022 | 1100.2 |
| 2023 | 1074.7 |
| 2024 | 862.7 |
| 2025 | 698.2 |
Cautions · 0317.8% of this theme group
Studies how larval nutrition and adult feeding affect lifespan and reproductive output.
Fecundity (149) · Longevity (241) · Larva (78) · Pupa (42)
Floral resources impact longevity and oviposition rate of a parasitoid in the field
Effects of Feeding Adults of<i>Hermetia illucens</i>(Diptera: Stratiomyidae) on Longevity, Oviposition, and Egg Hatchability: Insights Into
| Year | Share index |
|---|---|
| 2022 | 71.6 |
| 2023 | 61.5 |
| 2024 | 56.4 |
| 2025 | 55.0 |
Cautions · 0415.6% of this theme group
Investigates hormonal changes and trace element diets on oxidative stress and age‑related decline.
Internal medicine (57) · Endocrinology (46) · Senescence (112) · Oxidative stress (41)
Aging Reduces Estradiol Protection Against Neural but Not Metabolic Effects of Obesity in Female 3xTg-AD Mice
Ageing-associated effects of a long-term dietary modulation of four trace elements in mice
| Year | Share index |
|---|---|
| 2022 | 3572.6 |
| 2023 | 3799.3 |
| 2024 | 3524.0 |
| 2025 | 2568.1 |
Cautions · 0515.5% of this theme group
Considers implications of aging research for healthcare systems, pensions, and life expectancy planning.
Longevity (317) · Gerontology (61) · Life expectancy (63) · Pension (29)
Animal Models of Aging Research: Implications for Human Aging and Age-Related Diseases
Ageing, health, and health care
| Year | Share index |
|---|---|
| 2022 | 1944.7 |
| 2023 | 1916.2 |
| 2024 | 2260.4 |
| 2025 | 1488.8 |
Cautions · 068.5% of this theme group
Looks at genetic factors delaying leaf senescence and preserving seed longevity in crops.
Photosynthesis (31) · Germination (36) · Agronomy (28) · Botany (27)
Overexpression of a NAC transcription factor delays leaf senescence and increases grain nitrogen concentration in wheat
Comparative seed longevity under genebank storage and artificial ageing: a case study in heteromorphic wheat wild relatives
| Year | Share index |
|---|---|
| 2022 | 50.6 |
| 2023 | 41.8 |
| 2024 | 42.6 |
| 2025 | 42.9 |
Cautions · 073.4% of this theme group
Explores genotype‑dependent diet effects and stress responses on fruit fly lifespan.
Drosophila melanogaster (57) · Drosophila (17) · Longevity (49) · Organism (6)
The relationship between longevity and diet is genotype dependent and sensitive to desiccation in <i>Drosophila melanogaster</i>
Oxidative Effects of Gemifloxacin on Some Biological Traits of Drosophila melanogaster (Diptera: Drosophilidae)
| Year | Share index |
|---|---|
| 2022 | 46.1 |
| 2023 | 42.9 |
| 2024 | 45.0 |
| 2025 | 47.7 |
Opportunities · 0118.4% of this theme group
Reviews therapeutic potential of mesenchymal stem cells and senescence‑targeted interventions.
Senescence (865) · Cell biology (386) · Cellular senescence (123) · Stem cell (84)
Aging and Mesenchymal Stem Cells: Therapeutic Opportunities and Challenges in the Older Group
Cellular senescence: from homeostasis to pathological implications and therapeutic strategies
| Year | Share index |
|---|---|
| 2022 | 2072.7 |
| 2023 | 2301.1 |
| 2024 | 1979.5 |
| 2025 | 1393.7 |
Opportunities · 0217.0% of this theme group
Highlights compounds that mitigate oxidative damage and promote autophagic clearance in aging cells.
Senescence (548) · Oxidative stress (176) · Autophagy (104) · Inflammation (89)
Matrine Attenuates D‐Galactose‐Induced Aging‐Related Behavior in Mice <i>via</i> Inhibition of Cellular Senescence and Oxidative Stress
Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction
| Year | Share index |
|---|---|
| 2022 | 2213.8 |
| 2023 | 2098.4 |
| 2024 | 2149.1 |
| 2025 | 2355.1 |
Opportunities · 0316.1% of this theme group
Identifies genetic and molecular markers that predict and support extended healthy lifespan.
Longevity (754) · Gerontology (98) · Life expectancy (57) · Longevity risk (39)
Employing biomarkers of healthy ageing for leveraging genetic studies into human longevity
Comparative analyses of aging-related genes in long-lived mammals provide insights into natural longevity
| Year | Share index |
|---|---|
| 2022 | 1944.7 |
| 2023 | 1916.1 |
| 2024 | 2260.2 |
| 2025 | 1488.7 |
Opportunities · 0415.1% of this theme group
Shows how thermal regimes influence metabolic rate, longevity, and fecundity in model insects.
Longevity (498) · Fecundity (107) · Caenorhabditis elegans (130) · Drosophila melanogaster (74)
Effects of Temperature on Lifespan of Drosophila melanogaster from Different Genetic Backgrounds: Links between Metabolic Rate and Longevity
Fluctuating thermal regimes extend longevity and maintain fecundity to increase shelf‐life of <i>Drosophila melanogaster</i> cultures
| Year | Share index |
|---|---|
| 2022 | 97.6 |
| 2023 | 86.1 |
| 2024 | 79.8 |
| 2025 | 81.6 |
Opportunities · 0514.4% of this theme group
Develops targeted senolytics and examines mesenchymal stem cell lipid changes to improve vascular health.
Senescence (745) · Cell biology (323) · Mesenchymal stem cell (74) · Downregulation and upregulation (75)
Engineering Hierarchical Recognition‐Mediated Senolytics for Reliable Regulation of Cellular Senescence and Anti‐Atherosclerosis Therapy
Senescing Human Bone-Marrow-Derived\nClonal Mesenchymal\nStem Cells Have Altered Lysophospholipid Composition and Functionality
| Year | Share index |
|---|---|
| 2022 | 2295.1 |
| 2023 | 2493.8 |
| 2024 | 2075.3 |
| 2025 | 1703.6 |
Opportunities · 0611.3% of this theme group
Explores how manipulating cellular senescence can enhance tumor detection and treatment outcomes.
Cancer research (251) · Cancer (145) · Senescence (447) · Cancer cell (53)
Cellular senescence in cancer: from mechanisms to detection
Regulation of cellular senescence in tumor progression and therapeutic targeting: mechanisms and pathways
| Year | Share index |
|---|---|
| 2022 | 1965.9 |
| 2023 | 2741.0 |
| 2024 | 1885.1 |
| 2025 | 1574.5 |
Opportunities · 077.8% of this theme group
Analyzes transcriptional programs and mutant traits that delay leaf aging and boost stress tolerance.
Arabidopsis (85) · Senescence (343) · Chlorophyll (53) · Mutant (67)
High-Resolution Temporal Profiling of Transcripts during<i>Arabidopsis</i>Leaf Senescence Reveals a Distinct Chronology of Processes and Reg
Overexpression of<i>AtERF019</i>delays plant growth and senescence and improves drought tolerance in Arabidopsis
| Year | Share index |
|---|---|
| 2022 | 164.3 |
| 2023 | 148.8 |
| 2024 | 133.6 |
| 2025 | 137.8 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Promising | 37.9% | 37.4% |
| Descriptive | 26.5% | 17.4% |
| Breakthrough | 17.5% | 26.2% |
| Problem-identifying | 7.6% | 9.8% |
| Cautionary | 5.5% | 4.4% |
| Critical | 2.8% | 0.9% |
| Comparative | 2.2% | 3.8% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceA Perspective of AMD Through the Eyes of Immunology | 135 | 0.29% | 22 (16.3%) | 0.29% |
| Labour & data workLongevity and Lifetime Labor Supply: Evidence and Implications | 100 | 0.22% | 47 (47.0%) | 0.22% |
| Bias & fairnessIntergenerational actuarial fairness when longevity increases: Amending the retirement age | 12 | 0.03% | 5 (41.7%) | 0.03% |
| Safety & misuseExtrinsic Mortality Can Shape Life-History Traits, Including Senescence | 3 | 0.01% | 1 (33.3%) | 0.01% |
| Concentration of compute powerKilling death: Some implications of extending human lifespan indefinitely | 3 | 0.01% | 1 (33.3%) | 0.01% |
| Energy & datacenter footprintAging and Air Infusion Effects on the Performance and Longevity of Polyol Ester-Based Immersion Cooling Fluids for Data | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water useAging and Air Infusion Effects on the Performance and Longevity of Polyol Ester-Based Immersion Cooling Fluids for Data | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Hardware, e-waste & supply chain | 0 | 0.0% | 0 (%) | 0.0% |
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Compare demand signals in the United Kingdom’s newsflow with the age tech and longevity categories mapped to each signal.
Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.
The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.
Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.
Swipe horizontally to compare all columns →
| Signal family | Signal percentile | Supply percentile | Relative gap | Gap (points) | Signal share vs prior year |
|---|---|---|---|---|---|
| Diabetes, hypertension & cardiac burden ↗Disease Burden | 42.9 | 0.0 | +42.9 | +30.8% | |
| Mental health ↗Disease Burden | 78.6 | 50.0 | +28.6 | +41.2% | |
| Cancer burden ↗Disease Burden | 42.9 | 100.0 | -57.1 | -9.3% | |
| Air pollution ↗Environmental Driver | 14.3 | — | No matching category | — | +6.7% |
| Infectious outbreaks ↗Disease Burden | 28.6 | — | No matching category | — | +13.7% |
| Ageing & elder care ↗Disease Burden | 28.6 | — | No matching category | — | +4.8% |
| Maternal & child health ↗Disease Burden | 71.4 | — | No matching category | — | +33.0% |
| Layoffs & income shocks ↗Spending Pressure | 92.9 | — | No matching category | — | +37.0% |
Showing all 8 signals. Select a family for its history and mapped categories.
All 12 city readings for these demand families in the comparison geography. the United Kingdom is highlighted.
Each city’s reading is a share of its own coverage.
Maternal & child health · Infectious outbreaks · Cancer burden
Maternal & child health · Mental health · Cancer burden
Maternal & child health · Layoffs & income shocks · Cancer burden
Cancer burden · Maternal & child health · Layoffs & income shocks
Mental health · Layoffs & income shocks · Ageing & elder care
Maternal & child health · Cancer burden · Layoffs & income shocks
Cancer burden · Layoffs & income shocks · Maternal & child health
Cancer burden · Layoffs & income shocks · Mental health
Cancer burden · Ageing & elder care · Diabetes, hypertension & cardiac burden
Air pollution · Mental health · Maternal & child health
Layoffs & income shocks · Mental health · Maternal & child health
Maternal & child health · Layoffs & income shocks · Diabetes, hypertension & cardiac burden
Chronic cardiometabolic burden can turn into decades of management demand per patient.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 112 | 5.06 |
| 2024Q4 | 106 | 4.89 |
| 2025Q1 | 133 | 5.26 |
| 2025Q2 | 170 | 8.41 |
| 2025Q3 | 182 | 7.52 |
| 2025Q4 | 158 | 9.09 |
| 2026Q1 | 137 | 6.91 |
| 2026Q2 | 60 | 6.7 |
Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 161 | 7.27 |
| 2024Q4 | 222 | 10.25 |
| 2025Q1 | 200 | 7.91 |
| 2025Q2 | 204 | 10.09 |
| 2025Q3 | 362 | 14.95 |
| 2025Q4 | 193 | 11.1 |
| 2026Q1 | 222 | 11.19 |
| 2026Q2 | 99 | 11.05 |
Cancer burden can pull screening, diagnostics and oncology capacity demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 321 | 14.5 |
| 2024Q4 | 407 | 18.78 |
| 2025Q1 | 533 | 21.08 |
| 2025Q2 | 414 | 20.48 |
| 2025Q3 | 420 | 17.35 |
| 2025Q4 | 307 | 17.66 |
| 2026Q1 | 316 | 15.93 |
| 2026Q2 | 154 | 17.19 |
Sustained air-quality stress can pull respiratory and cardiac care demand with it.
This signal has no matching category in the page’s age tech and longevity market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 117 | 5.28 |
| 2024Q4 | 115 | 5.31 |
| 2025Q1 | 119 | 4.71 |
| 2025Q2 | 134 | 6.63 |
| 2025Q3 | 188 | 7.77 |
| 2025Q4 | 82 | 4.72 |
| 2026Q1 | 87 | 4.39 |
| 2026Q2 | 51 | 5.69 |
Outbreak pressure can pull testing, surveillance and rapid-care demand at short notice.
This signal has no matching category in the page’s age tech and longevity market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 74 | 3.34 |
| 2024Q4 | 133 | 6.14 |
| 2025Q1 | 145 | 5.74 |
| 2025Q2 | 120 | 5.94 |
| 2025Q3 | 176 | 7.27 |
| 2025Q4 | 90 | 5.18 |
| 2026Q1 | 114 | 5.75 |
| 2026Q2 | 43 | 4.8 |
An ageing base can shift demand toward geriatric, home and chronic care.
This signal has no matching category in the page’s age tech and longevity market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 128 | 5.78 |
| 2024Q4 | 219 | 10.11 |
| 2025Q1 | 215 | 8.5 |
| 2025Q2 | 186 | 9.2 |
| 2025Q3 | 276 | 11.4 |
| 2025Q4 | 97 | 5.58 |
| 2026Q1 | 163 | 8.22 |
| 2026Q2 | 82 | 9.15 |
Maternal and child burden can pull immunisation, nutrition and pediatric care demand.
This signal has no matching category in the page’s age tech and longevity market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 254 | 11.47 |
| 2024Q4 | 288 | 13.29 |
| 2025Q1 | 242 | 9.57 |
| 2025Q2 | 210 | 10.39 |
| 2025Q3 | 533 | 22.02 |
| 2025Q4 | 169 | 9.72 |
| 2026Q1 | 215 | 10.84 |
| 2026Q2 | 125 | 13.95 |
Layoff cycles can pull discretionary spend back toward value offerings.
This signal has no matching category in the page’s age tech and longevity market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 414 | 18.7 |
| 2024Q4 | 385 | 17.77 |
| 2025Q1 | 570 | 22.55 |
| 2025Q2 | 428 | 21.18 |
| 2025Q3 | 663 | 27.39 |
| 2025Q4 | 400 | 23.01 |
| 2026Q1 | 634 | 31.96 |
| 2026Q2 | 243 | 27.12 |
the United Kingdom age tech and longevity coverage
BMJ
1,387 citations in the snapshot
The Lancet
1,270 citations in the snapshot
1,226 citations in the snapshot
BMJ
692 citations in the snapshot
the United Kingdom coverage of this page's demand families
| Keyword | Recent articles | Prior articles | Share change |
|---|---|---|---|
| vaccine misinformation impact | 105 | 23 | 479.2% |
| continuing education immunization | 121 | 27 | 468.6% |
| vaccination-induced herd protection | 86 | 22 | 396.0% |
| pediatric catch-up vaccinations | 189 | 62 | 286.8% |
| exercise oncology | 67 | 47 | 80.9% |
| blood pressure reduction rate | 41 | 30 | 73.4% |
Share changes describe coverage in the stated comparison periods, not search demand or market size.
Company counts, hiring and disclosed funding across the recorded hubs.
71.9% across the displayed hubs
2 companies hiring · $301.2M disclosed funding
Explore companies in London ↗
6.1% across the displayed hubs
0 companies hiring · $7.4M disclosed funding
Explore companies in Bristol ↗
4.4% across the displayed hubs
1 companies hiring · $1.5M disclosed funding
Explore companies in Belfast ↗
4.4% across the displayed hubs
0 companies hiring · $0 disclosed funding
Explore companies in Birmingham ↗
3.5% across the displayed hubs
0 companies hiring · $0 disclosed funding
Explore companies in Nottingham ↗
3.5% across the displayed hubs
0 companies hiring · $51.1M disclosed funding
Explore companies in Edinburgh ↗
3.5% across the displayed hubs
0 companies hiring · $4.9M disclosed funding
Explore companies in Manchester ↗
2.6% across the displayed hubs
0 companies hiring · $0 disclosed funding
Explore companies in Kent ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 4 September 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗